Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Vertebral fracture assessment using a semiquantitative technique

Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691 · see citing works

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · see citing works

Effect of Risedronate on the Risk of Hip Fracture in Elderly Women

McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918 · see citing works

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 3× · see citing works

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580 · see citing works

Use of Inhaled Corticosteroids and Risk of Fractures

van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,297 · see citing works

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · see citing works

Use of oral corticosteroids and risk of fractures

Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263 · see citing works

Dose-Response and Trend Analysis in Epidemiology

Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,086 · see citing works

Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848 · see citing works

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. C. (2000) · Lara D. Veeken · doi:10.1093/rheumatology/39.12.1383 · Cited by 699 · see citing works

EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN

Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682 · see citing works

Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial

Reid, D. M., Hughes, R., Laan, R., Sacco-Gibson, N., Wenderoth, D., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 588 · see citing works

Use of oral corticosteroids in the United Kingdom

van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529 · see citing works

Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

Peel, N. F. A., Moore, D., Barrington, N. A., Bax, D. E., & Eastell, R. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.10.801 · Cited by 377 · see citing works

Rheumatoid arthritis, corticosteroid therapy and hip fracture.

Cooper, C. C., Coupland, C. A. C., & Mitchell, M. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.1.49 · Cited by 354 · see citing works

Fractures after rheumatoid arthritis a population‐based study

Hooyman, J. R., Melton, L. J., Nelson, A. M., O’Fallon, W. M., & Riggs, B. L. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780271205 · Cited by 283 · see citing works

Evaluation of factors associated with glucocorticoid‐induced osteopenia in patients with rheumatic diseases

Dykman, T. R., Gluck, O. S., Murphy, W. A., Hahn, T. J., & Hahn, B. H. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280402 · Cited by 281 · see citing works

Adverse effects of oral corticosteroids in relation to dose in patients with lung disease

Walsh, L. J. (2001) · Thorax · doi:10.1136/thorax.56.4.279 · Cited by 251 · see citing works

Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

Luengo, M., Picado, C., del Río, L., Guañabens, N., Montserrat, J. M., & Setoaín, J. (1991) · Thorax · doi:10.1136/thx.46.11.803 · Cited by 241 · see citing works

Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability

Johnell, O., Odén, A., Laet, C. E. D. H. D., Garnero, P., Delmas, P. D., & Kanis, J. A. (2002) · Osteoporosis International · doi:10.1007/s001980200068 · Cited by 195 · see citing works

Vertebral Fracture Risk With Long-term Corticosteroid Therapy

Naganathan, V., Jones, G., Nash, P. T., Nicholson, G. C., Eisman, J. A., & Sambrook, P. N. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.19.2917 · Cited by 141 · see citing works

Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind

Manolagas, S. C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1001 · Cited by 135 · see citing works

Comparison of Four Morphometric Definitions and a Semiquantitative Consensus Reading for Assessing Prevalent Vertebral Fractures

Grados, F., Roux, C., de Vernejoul, M. C., Utard, G., Jl, S., & Fardellone, P. (2001) · Osteoporosis International · doi:10.1007/s001980170046 · Cited by 110 · see citing works

Corticosteroids Do Not Alter the Threshold for Vertebral Fracture

Selby, P. L., Halsey, J. P., Adams, K., Klimiuk, P. S., Knight, S. M., Pal, B., Stewart, I. M. G., & Swinson, D. R. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.952 · Cited by 91 · see citing works

A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies

Ichikawa, K., Tsutsumi, A., Atsumi, T., Matsuura, E., Kobayashi, S., Hughes, G. R. V., Khamashta, M. A., & Koike, T. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11 · Cited by 88 · see citing works

Guidelines for prevention and treatment of glucocorticoid-induced osteoporosis

Compston, J. E. (2009) · Bone · doi:10.1016/j.bone.2009.07.039 · Cited by 39 · see citing works

Who Bears Responsibility for Glucocorticoid-Exposed Patients in a Large Health Maintenance Organization?

Ettinger, B. B., Pressman, A. R., & Shah, H. A. (2001) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2001.7.3.228 · Cited by 12 · see citing works

Untitled work

Santiago (2001) · doi:10.1002/1529-0131(200107)44:7

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

Papaioannou, A., Morin, S. N., Cheung, A. M., Atkinson, S. A., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A. B., Jamal, S. A., Kaiser, S., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,742 · see citing works

Epidemiology, etiology, and diagnosis of osteoporosis

Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,300 · see citing works

From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis

Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,210 · see citing works

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

CANALIS, E. M., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,118 · see citing works

Glucocorticoids Act Directly on Osteoblasts and Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength

O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2003) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771 · see citing works

Glucocorticoid-Induced Bone Disease

Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 698 · see citing works

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527 · see citing works

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial

Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493 · see citing works

Glucocorticoid-induced osteoporosis: an update

Compston, J. E. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 484 · see citing works

ACG clinical guideline: Preventive care in inflammatory bowel disease

Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473 · see citing works

Epidemiology of Vertebral Fractures

Schousboe, J. T. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.004 · Cited by 452 · see citing works

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

Hoes, J. N., Jacobs, J. W. G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E., Cutolo, M., da Silva, J. A. P., Esselens, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072157 · Cited by 410 · see citing works

The epidemiology of glucocorticoid-associated adverse events

McDonough, A. K., Curtis, J. R., & Saag, K. G. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f51031 · Cited by 404 · see citing works

Management of osteoporosis in postmenopausal women

(2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181c617e6 · Cited by 382 · see citing works

Glucocorticoid-Induced Osteoporosis and Osteonecrosis

Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 367 · see citing works

Glucocorticoid-induced osteoporosis: an update

Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362 · see citing works

High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study

Angeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., & Giustina, A. (2006) · Bone · doi:10.1016/j.bone.2006.02.005 · Cited by 361 · see citing works

Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice

Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355 · see citing works

Secondary Osteoporosis

Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 354 · see citing works

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

Strehl, C., Bijlsma, J. W. J., de Wit, M. P. T., Boers, M., Caeyers, N., Cutolo, M., Dasgupta, B., Dixon, W. G., Geenen, R., Huizinga, T. W. J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208916 · Cited by 342 · see citing works

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

Mirza, F., & CANALIS, E. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 334 · see citing works

Glucocorticoid-induced osteoporosis

Briot, K., & Roux, C. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000014 · Cited by 300 · see citing works

Fracture risk with intermittent high‐dose oral glucocorticoid therapy

de Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C. C., & van Staa, T. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22294 · Cited by 297 · see citing works

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

Suzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K., Sagawa, A., Takayanagi, R., Tanaka, H., et al. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0586-6 · Cited by 281 · see citing works

Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice

Weinstein, R. S., Wan, C., Liu, Q., Wang, Y., Almeida, M., O’Brien, C. A., Thostenson, J., Roberson, P. K., Boskey, A. L., Clemens, T. L., et al. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00545.x · Cited by 276 · see citing works

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use

Manson, S. C., Brown, R. E., Cerulli, A., & Vidaurre, C. F. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.01.003 · Cited by 275 · see citing works

Bone turnover markers: use in osteoporosis

Naylor, K. E., & Eastell, R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.86 · Cited by 263 · see citing works

Drug-induced Osteoporosis: Mechanisms and Clinical Implications

Mazziotti, G., CANALIS, E. M., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 259 · see citing works

The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis

van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 257 · see citing works

Corticosteroid-Induced Adverse Events in Adults

Fardet, L., Kassar, A., Cabané, J., & Flahault, A. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00005 · Cited by 254 · see citing works

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice

Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M. C., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23454 · Cited by 241 · see citing works

Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives

Seibel, M. J., Cooper, M. S., & Zhou, H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70045-7 · Cited by 230 · see citing works

Vertebral Fracture Assessment: The 2007 ISCD Official Positions

Schousboe, J. T., Vokes, T., Broy, S. B., Ferrar, L., McKiernan, F., Roux, C., & Binkley, N. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.008 · Cited by 214 · see citing works

Medication-induced osteoporosis: screening and treatment strategies

Panday, K., Gona, A., & Humphrey, M. B. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14546350 · Cited by 201 · see citing works

Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease

Saito, M., & Marumo, K. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9985-5 · Cited by 200 · see citing works

Influence of drugs on vitamin D and calcium metabolism

Gröber, U., & Kisters, K. (2012) · Dermato-Endocrinology · doi:10.4161/derm.20731 · Cited by 199 · see citing works

Management of glucocorticoid-induced osteoporosis

Compston, J. E. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.259 · Cited by 191 · see citing works

Glucocorticoid-induced osteoporosis: 2019 concise clinical review

Adami, G., & Saag, K. G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04906-x · Cited by 187 · see citing works

Osteocyte-Intrinsic TGF-β Signaling Regulates Bone Quality through Perilacunar/Canalicular Remodeling

Dole, N. S., Mazur, C. M., Acevedo, C., Lopez, J. P., Monteiro, D. A., Fowler, T. W., Gludovatz, B., Walsh, F., Regan, J. N., Messina, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.115 · Cited by 173 · see citing works

Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments

Lane, N. E. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00498-x · Cited by 173 · see citing works

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171 · see citing works

COPD and osteoporosis: links, risks, and treatment challenges

Inoue, D., Watanabe, R., & Okazaki, R. (2016) · International Journal of COPD · doi:10.2147/copd.s79638 · Cited by 171 · see citing works

Prevalence of Vertebral Fractures in Men with Acromegaly

Mazziotti, G., Bianchi, A., Bonadonna, S., Cimino, V., Patelli, I., Fusco, A., Pontecorvi, A., De Marinis, L., & Giustina, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0791 · Cited by 169 · see citing works

Glucocorticoids and bone: Local effects and systemic implications

Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168 · see citing works

Glucocorticoid-induced osteoporosis: who to treat with what agent?

Rizzoli, R., & Biver, E. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.188 · Cited by 166 · see citing works

Glucocorticoid-induced osteoporosis: An update on effects and management

Buehring, B., Viswanathan, R. K., Binkley, N., & Busse, W. W. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.040 · Cited by 163 · see citing works

Determinants of imminent fracture risk in postmenopausal women with osteoporosis

Barron, R., Oster, G., Grauer, A., Crittenden, D. B., & Weycker, D. A. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05294-3 · Cited by 160 · see citing works

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids

van Staa, T. P., Geusens, P., Pols, H. A. P., Laet, C. E. D. H. D., Leufkens, H. G. M., & Cooper, C. C. (2005) · QJM · doi:10.1093/qjmed/hci029 · Cited by 160 · see citing works

Secondary Osteoporosis and Metabolic Bone Diseases

Sobh, M., Abdalbary, M., Elnagar, S., Nagy, E., Elshabrawy, N. A., Abdelsalam, M., Asadipooya, K., & El-Husseini, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092382 · Cited by 159 · see citing works

Glucocorticoid dose determines osteocyte cell fate

Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157 · see citing works

Advances in Glucocorticoid-Induced Osteoporosis

den Uyl, D., Bultink, I. E. M., & Lems, W. F. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0173-y · Cited by 152 · see citing works

Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patients

Curtis, J. R., Westfall, A. O., Allison, J. J., Becker, A., Casebeer, L. L., Freeman, A. N., Spettell, C. M., Weissman, N., Wilke, S., & Saag, K. G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21194 · Cited by 151 · see citing works

Vertebral Fracture Assessment: The 2005 ISCD Official Positions

Vokes, T., Bachman, D. M., Baim, S., Binkley, N., Broy, S. B., Ferrar, L., Lewiecki, E. M., Richmond, B. J., & Schousboe, J. T. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2006.05.006 · Cited by 150 · see citing works

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

Devogelaer, J., Goemaere, S., Boonen, S., Body, J., Kaufman, J., Reginster, J., Rozenberg, S., & Boutsen, Y. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2032-z · Cited by 144 · see citing works

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Saag, K. G., Pannacciulli, N., Geusens, P., Adachi, J. D., Messina, O. D., Morales‐Torres, J., Emkey, R. D., Butler, P. W., Yin, X., & Lems, W. F. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40874 · Cited by 138 · see citing works

Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity

Weinstein, R. S. (2009) · Bone · doi:10.1016/j.bone.2009.06.030 · Cited by 135 · see citing works

Prevalence and predictors of fragility fractures in systemic lupus erythematosus

Yee, C., Crabtree, N. J., Skan, J., Amft, N., Bowman, S., Situnayake, D., & Gordon, C. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018127 · Cited by 130 · see citing works

2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis

Briot, K., Cortet, B., Roux, C., Fardet, L., Abitbol, V., Bacchetta, J., Buchon, D., Debiais, F., Guggenbuhl, P., Laroche, M., et al. (2014) · Joint Bone Spine · doi:10.1016/j.jbspin.2014.10.001 · Cited by 129 · see citing works

Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization

Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128 · see citing works

Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014

Cosman, F., Krege, J. H., Looker, A. C., Schousboe, J. T., Fan, B., Sarafrazi, N., Shepherd, J., Krohn, K., Steiger, P., Wilson, K. E., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3948-9 · Cited by 128 · see citing works

High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis

Graeff, C., Marín, F., Petto, H., Kayser, O., Reisinger, A., Peña, J. A., Zysset, P. K., & Glüer, C. (2012) · Bone · doi:10.1016/j.bone.2012.10.036 · Cited by 125 · see citing works

Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series

Armamento‐Villareal, R., Napoli, N., Diemer, K., Watkins, M. P., Civitelli, R., Teitelbaum, S. L., & Novack, D. V. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9263-5 · Cited by 118 · see citing works

Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength

Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 116 · see citing works

Glucocorticoid-induced Osteoporosis

Whittier, X., & Saag, K. G. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.005 · Cited by 112 · see citing works

Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines

Mazziotti, G., Formenti, A. M., Adler, R. A., Bilezikian, J. P., Grossman, A. B., Sbardella, E., Minisola, S., & Giustina, A. (2016) · Endocrine · doi:10.1007/s12020-016-1146-8 · Cited by 112 · see citing works

Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study

Claessen, K. M. J. A., Kroon, H. M., Pereira, A. M., Appelman-Dijkstra, N. M., Verstegen, M. J., Kloppenburg, M., Hamdy, N. A. T., & Biermasz, N. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2695 · Cited by 111 · see citing works

Understanding Bone Strength Is Not Enough

Hernandez, C. J., & van der Meulen, M. C. H. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3078 · Cited by 110 · see citing works

Skeletal Aging

Sfeir, J. G., Drake, M. T., Khosla, S., & Farr, J. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.03.011 · Cited by 109 · see citing works

Important Determinants of Bone Strength

Friedman, A. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000208612.33819.8c · Cited by 109 · see citing works

Autoimmune Myopathies: Updates on Evaluation and Treatment

McGrath, E. R., Doughty, C. T., & Amato, A. A. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00676-2 · Cited by 103 · see citing works

Osteoporosis

Khandelwal, S., & Lane, N. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.009 · Cited by 103 · see citing works

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis

Rossi, C. M., & Comite, G. D. (2008) · New England Journal of Medicine · doi:10.1056/nejmc073408 · Cited by 102 · see citing works

Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis

Balasubramanian, A., Wade, S. W., Adler, R. A., Lin, C. J. F., Maricic, M. J., O’Malley, C. D., Saag, K. G., & Curtis, J. R. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3646-z · Cited by 101 · see citing works

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

STOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., & SCHNITZER, T. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081207 · Cited by 100 · see citing works

Glucocorticoids: Complications to Anticipate and Prevent

Gensler, L. S. (2013) · The Neurohospitalist · doi:10.1177/1941874412458678 · Cited by 100 · see citing works

Osteoporosis Associated with Excess Glucocorticoids

Shaker, J. L., & Lukert, B. P. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.014 · Cited by 100 · see citing works

Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

Leib, E. S., Saag, K. G., Adachi, J. D., Geusens, P., Binkley, N., McCloskey, E. V., & Hans, D. B. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.05.014 · Cited by 98 · see citing works

Osteoporosis Associated with Chronic Obstructive Pulmonary Disease

Okazaki, R., Watanabe, R., & Inoue, D. (2016) · Journal of Bone Metabolism · doi:10.11005/jbm.2016.23.3.111 · Cited by 94 · see citing works

Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes

Gado, M., Baschant, U., Hofbauer, L. C., & Henneicke, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.835720 · Cited by 93 · see citing works

Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells

Hofbauer, L. C., & Rauner, M. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0069 · Cited by 91 · see citing works

Glucocorticoids, Inflammation and Bone

Güler-Yüksel, M., Hoes, J. N., Bultink, I. E. M., & Lems, W. F. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0335-7 · Cited by 91 · see citing works

Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency

Chakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0887 · Cited by 90 · see citing works

Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy–Induced Osteoporosis Treated With Alendronate or Teriparatide

Saag, K. G., Agnusdei, D., Hans, D. B., Kohlmeier, L., Krohn, K., Leib, E. S., Maclaughlin, E. J., Alam, J., Simonelli, C., Taylor, K. A., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39726 · Cited by 90 · see citing works

Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis

Fowler, T. W., Acevedo, C., Mazur, C. M., Hall‐Glenn, F., Fields, A. J., Bale, H., Ritchie, R. O., Lotz, J. C., Vail, T. P., & Alliston, T. N. (2017) · Scientific Reports · doi:10.1038/srep44618 · Cited by 90 · see citing works

The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice

Weinstein, R. S., Hogan, E. A., Borrelli, M. J., Liachenko, S. M., O’Brien, C. A., & Manolagas, S. C. (2017) · Endocrinology · doi:10.1210/en.2017-00662 · Cited by 88 · see citing works

Clinical reviews in allergy and immunology

Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87 · see citing works

Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score

Vinolas, H., Grouthier, V., Mehsen-Cêtre, N., Boisson, A., Winzenrieth, R., Schaeverbeke, T., Mesguich, C., Bordenave, L., & Tabarin, A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13743 · Cited by 86 · see citing works

Diabetes and bone

Hygum, K., Starup‐Linde, J., & Langdahl, B. L. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.05.001 · Cited by 86 · see citing works

From bone biology to clinical outcome: state of the art and future perspectives

Schett, G., Saag, K., & Bijlsma, J. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135061 · Cited by 88 · see citing works

Integrins, growth factors, and the osteoclast cytoskeleton

Zou, W., & Teitelbaum, S. L. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05245.x · Cited by 84 · see citing works

A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children

Hansen, K. E., Kleker, B., Safdar, N., & Bartels, C. M. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.02.002 · Cited by 84 · see citing works

Glucocorticoids and osteocyte autophagy

Yao, W., Dai, W., Jiang, J. X., & Lane, N. E. (2013) · Bone · doi:10.1016/j.bone.2013.01.034 · Cited by 82 · see citing works

Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system

Tanaka, Y., & Ohira, T. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.006 · Cited by 81 · see citing works

Osteoporosis in Chronic Obstructive Pulmonary Disease

Sarkar, M. S., Bhardwaj, R., Madabhavi, I., & Khatana, J. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s22803 · Cited by 80 · see citing works

Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide

Pereira, R. M. R., de Carvalho, J. F., de Paula, A. P., Zerbini, C. A. F., Domiciano, D. S., Gonçalves, H., Danowski, J. S., Neto, J. F. M., de Mendonça, L. M. C., Bezerra, M. C., et al. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000400009 · Cited by 80 · see citing works

Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases

Kochar, B. D., Cai, W., Cagan, A., & Ananthakrishnan, A. N. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15821 · Cited by 79 · see citing works

Biologic therapies and systemic bone loss in rheumatoid arthritis

Dimitroulas, T., Nikas, S. N., Trontzas, P., & Kitas, G. D. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.015 · Cited by 78 · see citing works

How to prevent steroid induced osteoporosis

Sambrook, P. N. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018556 · Cited by 78 · see citing works

Management of Osteoporosis in Patients Living With HIV—A Systematic Review and Meta-analysis

Starup‐Linde, J., Rosendahl, S. B., Storgaard, M., & Langdahl, B. L. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002207 · Cited by 77 · see citing works

Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis

Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 76 · see citing works

The Threshold of Bone Mineral Density for Vertebral Fracture in Female Patients with Glucocorticoid-induced Osteoporosis

Kaji, H., Yamauchi, M., Chihara, K., & Sugimoto, T. (2006) · Endocrine Journal · doi:10.1507/endocrj.53.27 · Cited by 58 · see citing works

Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.

Kumagai, S., Kawano, S., Atsumi, T., Inokuma, S., Okada, Y., Kanai, Y., Kanai, Y., Kaburaki, J., Kameda, H., Suwa, A., et al. (2005) · PubMed · Cited by 38 · see citing works

Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials

Amiche, M. A., Albaum, J. M., Tadrous, M., Pechlivanoglou, P., Lévesque, L. E., Adachi, J. D., & Cadarette, S. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3455-9 · Cited by 144 · see citing works

Predictors and bone density threshold for vertebral fracture in patients using oral glucocorticoids

van Staa, T. P., Cooper, C., Barton, I., Cohen, S., Reid, D. M., Laan, R. F. J. M., outcomes, P.-B. S. O. D. T. F. M. T. P., Utrecht, U., & wetenschappen, D. F. (2003) · Utrecht University Repository (Utrecht University)

Predictors for vertebral fractures and fracture threshold in patients using oral glucocorticoids

van Staa, T. P., Cooper, C. C., Barton, I. P., Cohen, S. F., Reid, D. M., & Laan, R. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology)